DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Quintiles IMS Holdings, Inc. (“QuintilesIMS”) (NYSE: Q) today announced
that its wholly owned subsidiary, Quintiles IMS Incorporated (the
“Issuer”), intends to raise €420 million in gross proceeds through an
offering of senior notes due 2025. QuintilesIMS also announced that the
Issuer delivered a conditional notice of redemption with respect to its
outstanding 4.125% euro-denominated senior notes due 2023.
QuintilesIMS today also announced that the Issuer intends to pursue an
amendment to its senior secured credit facility (the “Amendment”). The
terms of the Amendment are expected to provide for an incremental term
loan B of up to $750 million and to increase the Issuer’s restricted
payment capacity, among other things.
The net proceeds from the notes offering, together with the proceeds
from the Amendment, will be used to refinance certain indebtedness of
the Issuer, including the redemption of the 4.125% notes, to pay down
the Issuer’s revolving credit facility, to pay fees and expenses related
to the notes offering and the Amendment and for other general corporate
purposes, which may include share repurchases and acquisitions. The
consummation of the notes offering and the Amendment are each subject to
market and other conditions.
Certain statements in this press release are forward-looking statements.
These statements involve a number of risks, uncertainties and other
factors including the failure to consummate the notes offering and the
Amendment and potential changes in market conditions that could cause
actual results to differ materially.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the notes. The notes to be offered have
not been, and will not be, registered under the Securities Act of 1933
and may not be offered or sold in the United States absent registration
or an applicable exemption from the registration requirements of the
Securities Act of 1933. The notes are being offered only to qualified
institutional buyers in the United States in reliance on Rule 144A under
the Securities Act of 1933 and outside the United States only to
non-U.S. investors pursuant to Regulation S.
About QuintilesIMS
QuintilesIMS (NYSE:Q) is a leading integrated information and
technology-enabled healthcare service provider worldwide, dedicated to
helping its clients improve their clinical, scientific and commercial
results. Formed through the merger of Quintiles Transnational and IMS
Health, QuintilesIMS’s approximately 50,000 employees conduct operations
in more than 100 countries. Companies seeking to improve real-world
patient outcomes through treatment innovations, care provision and
access can leverage QuintilesIMS’s broad range of healthcare
information, technology and service solutions to drive new insights and
approaches. QuintilesIMS provides solutions that span clinical to
commercial, bringing customers a unique opportunity to realize the full
potential of innovations and advanced healthcare outcomes.
As a global leader in protecting individual patient privacy,
QuintilesIMS uses healthcare data to deliver critical, real-world
disease and treatment insights. Through a wide variety of
privacy-enhancing technologies and safeguards, QuintilesIMS protects
individual privacy while managing information to drive healthcare
forward. These insights and execution capabilities help biotech, medical
device and pharmaceutical companies, medical researchers, government
agencies, payers and other healthcare stakeholders in the development
and approval of new therapies, and to identify unmet treatment needs and
understand the safety, effectiveness and value of pharmaceutical
products in improving overall health outcomes.
QUINTILESIMSFIN
Click
here to subscribe to Mobile Alerts for QuintilesIMS.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170910005111/en/
Source: Quintiles IMS Holdings, Inc.